The long-term goal of this proposal is to discover and develop small molecule drugs against Head and Neck Cancers (HNC). The focus is on drug candidates that target processes critical for repopulation after radiation treatment. The current proposal is to perform preliminary pharmacokinetics and toxicity studies and test the efficacy of a proprietary drug candidate on preclinical models of human HNC. Head and Neck Cancers remain hard to control even with surgery and high doses of radiation, both of which have devastating side effects. New drugs that enhance standard therapies by reducing resistance and preventing re-population after these treatments have the potential to improve clinical practices. Successful completion of this project will yield a drug candidate that can be carried into PD/ADME/toxicology analysis towards IND filing.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research – Phase I (N43)
Project #
261201300021C-0-0-1
Application #
8739890
Study Section
Project Start
2013-09-12
Project End
2014-06-11
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$249,672
Indirect Cost
Name
Suvica, Inc.
Department
Type
DUNS #
963360719
City
Boulder
State
CO
Country
United States
Zip Code
80307